MIAMI, Jan. 08, 2021 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader in digital therapeutics, announced today Patrick Gallagher has joined Ehave as Sales and Customer Acquisition Director. Mr. Gallagher will be responsible for building key customer relationships, sales channels for the Ehave Dashboard, and the suite of products offered through Ehave and its joint partnerships.
Mr. Gallagher has over 20 years of experience as a results-proven sales professional and corporate consultant. He has consulted with more than 400 organizations across the U.S. with a primary focus on developing executive business strategies in sales, operations, marketing, strategy, and building a competitive advantage. Mr. Gallagher also brings a vast amount of experience selling intangible products including health and welfare solutions, executive benefits, HR consulting, benefit enrollment technologies, wellbeing and engagement strategies, multinational benefits, retirement plan design and consulting, organizational & leadership development, and pharmacy benefit management.
“I’m honored to be joining Ehave and look forward to sharing the advancements the Company has made in digital therapeutics for mental health,” Mr. Gallagher said. “I’m passionate about giving back, and knowing that Ehave helping the people who need it most, is truly gratifying.”
“Patrick has the experience and knowledge needed to lead our sales team during this time of rapid growth and development,” said Ben Kaplan, Ehave CEO. “As we expand develop deeper relationships with our partners, we will be helping even more people heal their mental health with a full snapshot of their entire health, which is so important right now.”
Additional Ehave Inc. Information
We are truly grateful for the support of EHVVF shareholders! Please join the conversation on our Ehave supporters’ telegram group at https://t.me/EhaveInc.
The company posts important information and updates through weekly videos from the official company YouTube channel https://www.youtube.com/channel/UCnyW1mgMd0qmYkEMq3O6FWA.
Please follow Ehave on Twitter @Ehaveinc1
About Ehave, Inc.
Ehave, Inc. (EHVVF) is a leader in digital therapeutics and developer of KetaDASH, a home delivery platform for patients who have been prescribed Ketamine infusions. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. The Ehave Telemetry Portal is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine-learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. Ehave also owns 75.77% of psychedelic company 20/20 Global’s outstanding shares. Additional information on Ehave can be found on the Company’s website at: www.ehave.com.
Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.
For Investor Relations, please contact:
Phone: (623) 261-9046